RXII - RXi Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.425
-0.005 (-1.16%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close0.430
Open0.440
Bid0.430 x 1400
Ask0.450 x 800
Day's Range0.425 - 0.450
52 Week Range0.400 - 7.700
Volume555,495
Avg. Volume996,049
Market Cap1.86M
Beta (3Y Monthly)1.86
PE Ratio (TTM)N/A
EPS (TTM)-3.040
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • Zacks Small Cap Research15 days ago

    RXII: Dilution Impact from Share Issuance

    On October 3rd, 2018 RXi Pharmaceuticals Corp. (RXII) announced it had closed its $15 million public underwriting. 3.725 million shares were issued at $0.70 per share and 17.702 million prefunded warrants were issued at $0.69 per share with a $0.01 exercise price. 21.427 million seven year warrants were also issued with an exercise price of $0.70.

  • PR Newswire20 days ago

    RXi Pharmaceuticals Announces Closing Of $15 Million Underwritten Public Offering

    MARLBOROUGH, Mass., Oct. 3, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today announced the closing of its previously announced underwritten public offering of 3,725,714 units at a public offering price of $0.70 per unit and 17,702,858 pre-funded units at a public offering price of $0.69 per pre-funded unit, raising gross proceeds of approximately $15 million. The Company intends to use the net proceeds of this offering towards the development of RXi's immuno-oncology program, for other research and development activities and for general working capital. Each unit sold in this offering contained one share of common stock and one warrant to purchase one share of common stock.

  • PR Newswire22 days ago

    RXi Pharmaceuticals Announces Pricing Of $15 Million Upsized Underwritten Public Offering

    MARLBOROUGH, Mass., Oct. 1, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today announced the pricing of an underwritten public offering of 21,428,572 units at a price to the public of $0.70 per unit. Each unit contains one share of common stock (or common stock equivalent) and one warrant to purchase one share of common stock.

  • ACCESSWIRE25 days ago

    Today's Research Reports on Stocks to Watch: RXi Pharmaceuticals and Geron

    NEW YORK, NY / ACCESSWIRE / September 28, 2018 / Rxi Pharmaceuticals saw its shares soaring on Thursday as the company presented a poster entitled, "The Use of Self-delivering RNAi to Enhance NK Cell Cytotoxicity," at the 16th Annual Discovery on Target Conference. Geron shares were going in the opposite direction and crashed hard after Wall Street learned that its collaboration with Johnson & Johnson has come to an end. RXi Pharmaceuticals Corporation shares were up a little over 28% at the close on Thursday.

  • PR Newswire27 days ago

    RXi Pharmaceuticals to Present New Data from its Immuno-Oncology Program Using sd-rxRNA Therapeutic Compounds Targeting Intracellular Checkpoint Cbl-b in NK Cells at the 16th Annual Discovery on Target Conference

    - RXi to present a poster today, Wednesday, September 26, 2018 - Advancements in the Company's immuno-oncology programs will be presented demonstrating the potential of sd-rxRNA in NK cells for the use ...

  • Zacks Small Cap Research2 months ago

    RXII: Dermal & Ocular Assets Available for Sale

    During the second quarter, RXi obtained additional financing to continue the development of its immuno-oncology program, provided readouts for Samcyprone and RXI-109 in retinal scarring and developed a research collaboration with autologous TIL leader, Iovance. The area of immediate interest is the status of the dermatology and ocular assets which have all provided data available for potential suitors to review. RXi is dependent on an upfront payment from these assets to support the oncology programs that are in development.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of RXII earnings conference call or presentation 14-Aug-18 8:30pm GMT

    Q2 2018 Rxi Pharmaceuticals Corp Earnings Call

  • PR Newswire2 months ago

    RXi Pharmaceuticals and Karolinska Institutet Enter into Collaboration to Develop sd-rxRNA Compounds to Improve Functionality and Persistence of T Cells and NK Cells for the Advancement of Immuno-Oncology Therapeutics for Solid Tumors

    MARLBOROUGH, Mass. , Aug. 15, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...

  • ACCESSWIRE2 months ago

    RXi Pharmaceuticals Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 14, 2018 / RXi Pharmaceuticals Corporation (NASDAQ: RXII ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM ...

  • PR Newswire2 months ago

    RXi Pharmaceuticals Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

    - Extended cash runway by securing net proceeds of $4.2 million in April 2018 - Announced positive results from dermatology and ophthalmology clinical trials enabling advancement of potential partnerships ...

  • PR Newswire3 months ago

    RXi Pharmaceuticals to Webcast Second Quarter 2018 Financial Results on Tuesday, August 14, 2018

    MARLBOROUGH, Mass. , Aug. 7, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...

  • Zacks Small Cap Research3 months ago

    RXII: RXI-109 Results! Finally...

    On August 1st RXi Pharmaceuticals (RXII) issued a press release announcing positive results from their RXI-109-1501 Phase I/II trial for retinal scarring. There were a total of 25 adverse events, but the majority were mild and the remaining seven were moderate. No dose limiting toxicities or serious toxicities were observed.

  • PR Newswire3 months ago

    RXi Pharmaceuticals Granted Patents for sd-rxRNA Technology Strengthening Intellectual Property Estate in Europe and Japan

    MARLBOROUGH, Mass. , Aug. 2, 2018 /PRNewswire/ --  RXi Pharmaceuticals Corporation (NASDAQ: RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: RXi Pharmaceuticals and Neurocrine Biosciences

    NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Strong second quarter results and sales of Ingrezza sent shares of Neurocrine Biosciences higher on Wednesday to a new high and a market cap of over $10 billion. Shares of Rxi Pharmaceuticals also soared on positive study results. RXi Pharmaceuticals Corporation shares closed up 20.95% on Wednesday on nearly 13.2 million shares traded.

  • PR Newswire3 months ago

    RXi Pharmaceuticals Announces Positive Results From Phase 1/2 Trial With RXI-109 For Retinal Scarring

    - RXI-109 is a self-delivering RNAi (sd-rxRNA®) compound that targets connective tissue growth factor (CTGF), a key regulator of fibrosis and scar formation. - Study successfully meets primary objective by showing that RXI-109 is safe and well tolerated in this dose escalation study. MARLBOROUGH, Mass., Aug. 1, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform, today announced positive results with RXI-109 in a Phase 1/2 clinical trial.

  • ACCESSWIRE4 months ago

    Complimentary Technical Snapshots on Verastem and Three More Biotech Stocks

    Stock Research Monitor: RXII, SAGE, and SGMO LONDON, UK / ACCESSWIRE / July 6, 2018 / If you want a free Stock Review on VSTM sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com ...

  • PR Newswire4 months ago

    BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury

    Unlike other SCI drugs in clinical development that target growth inhibition in the central nervous system (CNS), BA-434 targets intrinsic barriers to axon regeneration.  After neurotrauma, neurons in the central nervous system do not spontaneously regenerate their injured axons.  Intrinsic barriers to regeneration refer to the diminished ability of adult CNS neurons to regenerate.  PTEN is known to be an intrinsic barrier to regeneration and BA-434 uses RXi's self-delivering RNA interference therapeutic platform to block PTEN expression.

  • Business Wire4 months ago

    BioAxone BioSciences Awarded $1.1 Million Phase 2 SBIR Funding for Continued Development of sd-rxRNA Drug Candidate for the Treatment of Spinal Cord Injury

    BioAxone BioSciences, Inc. announced today that, as part of a collaborative effort with RXi Pharmaceuticals Corporation (RXII), it is the recipient of a grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the agency’s SBIR Phase II funding program. This two-year grant provides funding for further development of BioAxone’s preclinical candidate BA-434, a novel sd-rxRNA® compound that targets PTEN for the treatment of spinal cord injury (SCI). After neurotrauma, neurons in the central nervous system do not spontaneously regenerate their injured axons.

  • ACCESSWIRE5 months ago

    Sangamo Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space

    This Wednesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Riot Blockchain Inc. (NASDAQ: RIOT), RXi Pharmaceuticals Corp. (NASDAQ: RXII), Sage Therapeutics Inc. (NASDAQ: SAGE), and Sangamo Therapeutics Inc. (NASDAQ: SGMO).All you have to do is sign up today for this free limited time offer by clicking the link below. Castle Rock, Colorado-based Riot Blockchain Inc.'s stock finished Tuesday's session 0.91% higher at $7.80 with a total trading volume of 296,284 shares.

  • PR Newswire5 months ago

    RXi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone™ for the Treatment of Common Warts

    - Samcyprone™ is a proprietary topical formulation of the small molecule diphenylcyclopropenone (DPCP), a topical immunomodulator that works by initiating a T-cell response. MARLBOROUGH, Mass., May 18, 2018 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII) a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today announced the positive results of its Phase 2 clinical trial, RXI-SCP-1502. The primary effectiveness objectives were met as shown by high levels of immunotherapeutic response and therapeutic response.

  • ACCESSWIRE5 months ago

    Blog Exposure - RXi Pharma and Iovance Biotherapeutics Announce Research Collaboration

    LONDON, UK / ACCESSWIRE / May 15, 2018 / If you want access to our free research report on RXi Pharma Corp. (NASDAQ: RXII), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=RXII as the Company's latest news hit the wire. On May 11, 2018, the Company announced that it has inked a research collaboration deal with Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance") to evaluate the potential synergies with RXi's novel sd-rxRNA therapeutic compounds and Iovance's autologous cell therapy based on tumor-infiltrating lymphocytes (TILs), for use in the treatment of cancer.

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of RXII earnings conference call or presentation 10-May-18 8:30pm GMT

    Q1 2018 Rxi Pharmaceuticals Corp Earnings Call

  • Zacks Small Cap Research5 months ago

    RXII: Partner Relationships in TILs to Drive Future Value

    RXi reported revenues of $23,000 for the quarter from grants related to BioAxone’s work in spinal cord injury, compared to zero in revenues in 1Q:17. Following the availability of the trial results, RXi will set up data rooms for interested buyers.

  • Benzinga5 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Trade Desk Inc (NASDAQ: TTD ) stock soared nearly ...